San Francisco startup Framework Therapeutics is likewise working on an oral, once-day-to-day GLP-1 drug termed GSBR-1290—the drug surpassed Wall Street’s anticipations in June when a mid-phase study showed typical weight loss of around six% and it programs to begin An additional mid-stage trial in the direction of the top of this year—that fo… Read More